Politics

GOP Senators Criticize FDA Pace on Mifepristone Safety Review, Threaten Legislative Action

Illustration for: GOP Senators Criticize FDA Pace on Mifepristone Safety Review, Threaten Legislative Action
AI-generated illustration. Visual interpretation does not represent real individuals or scenes.

Feb 12, 2026

THE BARE STORY

Republican senators expressed frustration on Tuesday following a closed-door briefing with FDA Commissioner Marty Makary regarding a safety review of the abortion drug mifepristone. Senators Josh Hawley and Bill Cassidy criticized the agency for what they described as a lack of progress on a promised study of the medication, which is used in a majority of abortions in the United States.

Following the meeting, Senator Hawley stated that Commissioner Makary provided no timeline for the review or confirmation of its current status. Hawley said he has "no confidence" the agency is acting with urgency and announced plans to involve Congress. He indicated he may seek to place restrictions on the drug through government funding legislation or a standalone bill in the coming weeks. Senator Cassidy, who arranged the briefing, echoed these sentiments, calling the lack of progress disappointing.

In response to the criticism, a Department of Health and Human Services spokesperson referred to a previous statement noting that the FDA is conducting the study properly. The statement explained that such reviews often take a year or more to complete to ensure scientific standards are met.

To support his call for stricter oversight, Hawley cited a study by the Ethics and Public Policy Center which alleged that nearly 11% of women who used the drug experienced serious adverse events within 45 days. The senator argued for the reinstatement of safeguards removed by the Biden administration, including requirements for in-person doctor visits to obtain prescriptions and follow-up care.

The dispute occurs as the Trump administration faces pressure to restrict access to abortion pills via mail and telemedicine. While the administration reportedly asked judges in ongoing lawsuits to delay rulings until the FDA’s study is finished, conservative lawmakers are pushing for immediate action to limit the drug's availability.

Same Facts. Different Perspectives.

Two AI models. Two viewpoints. One factual foundation.

Perspective by Grok

• Enforcing Public Safety Standards Prioritizing the protective role of the state, this camp argues that the EPPC study citing "serious adverse events" in nearly 11% of users necessitates immediate government intervention. The logic dictates that when credible data suggests harm, the "lack of progress" on a safety review is not bureaucratic caution but negligence. The demand to reinstate safeguards is viewed as a moral obligation to restore the standard of care and protect citizens from potential medical complications.

• Restoring Congressional Oversight Valuing the supremacy of elected representatives over unelected officials, this perspective sees Commissioner Makary’s failure to provide a "timeline" or confirmation of status as a breach of accountability. The threat to utilize "standalone bills" or funding legislation is interpreted as a valid exercise of checks and balances against an unresponsive administrative state. If the agency refuses to act with urgency, the legislature is duty-bound to impose order and responsiveness.

• Reinstating Institutional Continuity Focusing on established medical norms, this camp views the previous administration's removal of requirements like "follow-up care" as a reckless deregulation that disrupted the traditional doctor-patient relationship. The push to return to in-person visitation is reasoned not as a restriction, but as a return to prudent medical practice. This side seeks to stabilize the healthcare system by reverting to long-standing protocols that prioritize physical examination over tele-health conveniences.

How it may affect me

As a U.S. reader:

Patients seeking medication abortions via telemedicine could face new barriers if proposed legislative actions successfully mandate in-person doctor visits and follow-up care.

Americans awaiting legal certainty on the availability of abortion pills by mail may see court rulings delayed for a year or more while the FDA completes its safety review.

The federal funding process could become complicated in the coming weeks if lawmakers follow through on threats to attach drug restrictions to government spending legislation.

Those using the drug may eventually be subject to reinstated safety protocols, such as mandatory physical examinations, if arguments regarding adverse event rates drive policy changes.

Read the story at

Note: All TheBareNews content is AI-generated. For additional context, reporting, and updates, you are invited to explore the news outlets linked above.